UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------
FORM 13F
FORM 13F COVER PAGE
Report for the Calendar Year or Quarter Ended: March 31, 2013
Check here if Amendment [ ]; Amendment Number: __________
This Amendment (Check only one.): [ ] is a restatement.
[ ] adds new holding entries.
Institutional Investment Manager Filing this Report:
Name: VHCP Management, LLC
Address: 3340 Hillview Avenue
Palo Alto, California 94304
Form 13F File Number: 28- __________
The institutional investment manager filing this report and the person by whom
it is signed hereby represent that the person signing the report is authorized
to submit it, that all information contained herein is true, correct and
complete, and that it is understood that all required items, statements,
schedules, lists, and tables, are considered integral parts of this form.
Person Signing this Report on Behalf of Reporting Manager:
Name: David Stepp
Title: General Counsel, VR Management, LLC
Phone: (650) 561-9580
Signature, Place, and Date of Signing:
/s/ David L. Stepp Palo Alto, California May 14, 2013
--------------------
[Signature]
Report Type (Check only one.):
[X]13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager
are reported in this report)
[ ]13F NOTICE. (Check here if no holdings reported are in this report, and all
holdings are reported by other reporting manager(s).)
[ ]13F COMBINATION REPORT. (Check here if a portion of the holdings for this
reporting manager are reported in this report and a portion are reported by
other reporting manager(s).)
FORM 13F SUMMARY PAGE
Report Summary:
-
Number of Other Included Managers: 0
Form 13F Information Table Entry Total: Fifteen (15)
Form 13F Information Table Value Total: $131,873,000
List of Other Included Managers: None
FORM 13F INFORMATION TABLE
Voting Authority
TITLE OF VALUE SHARES / SH / PUT / INVESTMENT OTHER ---------------------
NAME OF ISSUER CLASS CUSIP (X$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE
-------------- -------- ----------- -------- --------- ---- ----- ---------- -------- --------- ------ ----
Alexza Pharmaceuticals, Inc. COM 015384 10 0 2,210 499,999 SH N/A Sole N/A 499,999 N/A N/A
Amicus Therapeutics, Inc. COM 03152W 10 9 520 164,000 SH N/A Sole N/A 164,000 N/A N/A
Anacor Pharmaceuticals, Inc. COM 032420 10 1 10,406 1,610,856 SH N/A Sole N/A 1,610,856 N/A N/A
Anthera Pharmaceuticals, Inc. COM 03674U 10 2 949 1,437,623 SH N/A Sole N/A 1,437,623 N/A N/A
BioCryst Pharmaceuticals, Inc. COM 09058V 10 3 468 392,990 SH N/A Sole N/A 392,990 N/A N/A
Biodel, Inc. COM 09064M 10 5 3,614 1,274,000 SH N/A Sole N/A 1,274,000 N/A N/A
Chelsea Therapeutics
International, Inc. COM 163428 10 5 5,134 2,516,870 SH N/A Sole N/A 2,516,870 N/A N/A
Dyax Corp. COM 26746E 10 3 5,824 1,335,714 SH N/A Sole N/A 1,335,714 N/A N/A
GTx, Inc. COM 40052B 10 8 7,359 1,773,242 SH N/A Sole N/A 1,773,242 N/A N/A
Hyperion Therapeutics, Inc COM 44915N 10 1 6,584 255,000 SH N/A Sole N/A 255,000 N/A N/A
Ironwood Pharmaceuticals, Inc. COM 46333X 10 8 32,913 1,800,000 SH N/A Sole N/A 1,800,000 N/A N/A
Keryx Biopharmaceuticals, Inc. COM 492515 10 1 14,434 2,048,773 SH N/A Sole N/A 2,048,773 N/A N/A
Neurocrine Biosciences, Inc. COM 64125C 10 9 23,881 1,964,673 SH N/A Sole N/A 1,964,673 N/A N/A
Tesaro, Inc. COM 881569 10 7 14,424 656,813 SH N/A Sole N/A 656,813 N/A N/A
Threshold Pharmaceuticals, Inc. COM 885807 20 6 3,153 684,000 SH N/A Sole N/A 684,000 N/A N/A